Cullinan Therapeutics Hits New 52-Week Low at $5.89

Cullinan Therapeutics, Inc., a player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 5.89 on September 17, 2025. This significant decline reflects a challenging year for the company, with its stock price plummeting by 74.18% over the past year, contrasting sharply with the S&P 500's performance of 17.28% during the same period.
The company's market capitalization stands at approximately USD 404 million, indicating its position within the industry. Cullinan Therapeutics is currently operating at a loss, as evidenced by its negative price-to-earnings ratio and a return on equity of -42.01%. Additionally, the stock's price-to-book ratio is recorded at 0.82, suggesting that the market values the company below its book value.

With no dividend yield and a debt-to-equity ratio of -0.54, Cullinan Therapeutics is navigating a complex financial landscape. The stock's previous 52-week high was noted at USD 18.62, highlighting the volatility and challenges faced by the company in the current market environment.